Clinical Trial Update: A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of praliciguat in participants with focal segmental glomerulosclerosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Praliciguat (praliciguat)

Snippet

Sponsor: Akebia Therapeutics | Conditions: Focal Segmental Glomerulosclerosis | Phase 2 | Status: RECRUITING